NRR to be available exclusively on OvidSP online search and discovery platform to all Ovid customers

As part of ongoing efforts to strengthen its presence in China's healthcare information market, Ovid, a part of Wolters Kluwer Health and a global leader in electronic scientific, medical, and academic information research solutions, is pleased to announce an agreement with Neural Regeneration Research (NRR), an English-language monthly journal dedicated to presenting peer-reviewed, evidence-based scholarly research in stem cells and regeneration.

NRR will be available exclusively on OvidSP, via the OvidSP electronic search and discovery platform, to all Ovid customers globally. NRR is published by the publishing house of Neural Regeneration Research and China Science Press, and sponsored by the Chinese Rehabilitation Medical Association and supervised by China's Ministry of Health.

"China is a strategic growth area for us, and we're especially excited to offer this prestigious title, Neural Regeneration Research, which publishes cutting-edge, evidence-based research and boasts a highly regarded and rigorous international editorial board," said Karen Abramson, President & CEO of Wolters Kluwer Health Medical Research. "Partnering on this initiative with our colleagues at Wolters Kluwer China has been absolutely critical to our success in working with the NRR team and China Science Press."

Added Lisha Wang, Editor-in-Chief of Neural Regeneration Research, "Wolters Kluwer's global brand recognition and publishing innovation, combined with the strength of the OvidSP platform, widely recognized as a leading healthcare information search tool, will enable us to bring our content to the wider medical community around the world."

Neural Regeneration Research (NRR) is renowned inside and outside of China for its dedication to publishing timely and practical original research and developments in the field of neuroregeneration, with contributions from experts in neuroanatomy, pathology, physiology, biochemistry, pharmacology, immunology, and auxanology. Topics include the influences of neural stem cells, neuroengineering, neurodegeneration, and traditional Chinese medicine and acupuncture intervention. NRR focuses on publishing meta-analysis articles with Chinese characteristics; evidence-based case clinical research articles; analysis of gene polymorphism related to region, nationality, and demography; review articles regarding new technology and new therapy; multi-center, large-sample, randomized, and controlled articles and reports; and more.

The Journal's Editorial Committee is comprised of an international panel of academics to ensure that high quality is maintained. It has 92 international board members from 27 countries and 238 Chinese board members. Each manuscript is reviewed by 4-6 randomly selected editors. NRR boasts a rejection rate of 80% of submitted articles.

NRR will be accessible on OvidSP's Journals@Ovid portal, which offers quick, easy access to approximately 1,200 premium and largely peer-reviewed journals in medicine and science--virtually none of which are embargoed. Significantly, users can search full-text articles via Journals@Ovid simultaneously with other e-resources for a streamlined, comprehensive search experience.